2020年2月3日 · These small peptides prevent the cardiovascular side effects of EPO and are promising as clinical drugs. This review briefly introduces the receptors and tissue-protective effects of EPO and...

Human erythropoietin (EPO) is a peptide hormone produced in the fetal liver during early development and the kidneys in the human adult body. As a major hematopoietic growth factor (HGF), it regulates bone marrow erythropoiesis by promoting the daily massive production (200 billion) of RBCs full of hemoglobin A (α 2 β 2 ), that carry oxygen ...

Endogenous Epo, its recombinant analogs and Epo-mimetic peptides can bind to the homodimeric EpoR. The EpoR then recruits JAK-2 that catalyzes EpoR/JAK-2 transphosphorylation. The phosphorylated EpoR induces activation of the signal transducer and activator of transcription 5 (STAT-5), the phosphatidyl …

2021年8月20日 · Human erythropoietin (EPO) is an N-linked glycoprotein consisting of 166 aa that is produced in the kidney during the adult life and acts both as a peptide hormone and hematopoietic growth factor (HGF), stimulating bone marrow erythropoiesis. EPO production is activated by hypoxia and is regulated v …

Comparison of the biological properties of agonist and antagonist EMPs with EPO suggests that the extracellular domain orientation is tightly coupled to the cytoplasmic signaling events and,...

2017年8月17日 · In this study, we examined the potential of a novel EPO-based short peptide, MK-X, as a novel drug for stroke treatment in comparison with EPO. We found that MK-X administration with...

2022年2月1日 · In this study, we generated divergently modified new peptide analogs derived from helix C of EPO, with several amino acid replacements that interact with erythropoietin receptors (EPORs). This modification resulted in unique binding potency to EPOR.

2000年9月1日 · Peptide mimics of Epo. The Epo receptor (EPOR) is a member of a superfamily of cytokine receptors which includes receptors for growth hormone (GH), granulocyte‐colony stimulating factor (G‐CSF), thrombopoietin (TPO) and others .

Erythropoietin (EPO) mimetic peptides (EMPs) activate the EPO receptor but have no structural analogy to EPO, offering the potential for lower cost as they are not biologic drugs. The first approved EMP, peginesatide, was withdrawn from the market within a year of its approval because of fatal anaphylactic reactions.

2018年1月1日 · As an alternative, nonerythropoietic EPO mimetic peptides can be used as candidate drugs with their high potency and selectivity, easy production, low cost, and immunogenicity properties. Recent experimental studies suggest that these peptides prevent ischemic brain injury and neuroinflammation.